Seliciclib trial for Cushing disease from a pituitary tumor
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This Phase 2 study tests seliciclib (also called R-roscovitine) in people with Cushing disease caused by a pituitary tumor and ongoing high cortisol levels. It may help reduce excess cortisol production in those whose Cushing disease has not fully gone away or has come back after standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 18 or older.
- Your Cushing disease must be confirmed as pituitary-related by hormone tests and scans (not adrenal or other causes).
- Your urine cortisol (UFC) must be persistently high on two separate 24-hour tests (at least 1.5× the normal upper limit).
- You are already being treated for Cushing disease, and any related medications must be stopped for the required “washout” time before screening.
- You must have eye/vision checks that are stable and not show compression of the optic nerve/chiasm from the tumor.
- Your heart, liver, kidneys, electrolytes, and diabetes must be in acceptable ranges (examples include potassium ≥3.5 and HbA1c ≤8%).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests fimepinostat (a targeted cancer-style drug) to help control Cushing disease caused by a pituitary tumor. It’s mainly for adults whose Cushing is confirmed to come from the pituitary and who meet safety and medication-washout rules.
This study checks long-term health in people who were treated successfully for Cushing disease when they were under 21. It also collects information from family members to study genetic links to pituitary tumors.
This is a study that collects and reviews information about how people with Cushing’s syndrome (including some mild forms and certain “silent” tumors) are diagnosed and treated, and what outcomes they have. It may help researchers understand which treatments work best in different types of the condition.
This study tests a special type of brain scan (PET-MRI) to better find tiny pituitary tumors causing Cushing's disease. It may help people whose standard MRI didn't show a clear tumor.
This trial tests whether osilodrostat can lower blood pressure in people with Cushing's syndrome whose high blood pressure is not well controlled by their current medications. The drug works by reducing the production of the stress hormone cortisol, which is abnormally high in Cushing's syndrome.
This trial tests whether taking two medications together—osilodrostat and cabergoline—can help control Cushing's disease by lowering excess cortisol levels. Cushing's disease is caused by a pituitary tumor that makes too much of a hormone called ACTH, which drives cortisol overproduction.
Hear when a new Cushing Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.